Objective To evaluate the clinical efficacy and safety of Bruton's tyrosine kinase(BTK)inhibitors for elderly or infirm patients with primary central nervous system lymphoma(PCNSL),and to assess the post-treatment survival outcomes.Methods Date of 15 elderly and infirm PCNSL patients treated at Shenzhen Hospital of Peking University between March 2018 and March 2023 were retrospectively analyzed.The treatment regimen included induction or maintenance therapy with BTK inhibitors.The key endpoints included progression-free survival(PFS),overall survival(OS),and adverse events.Results The median duration of maintenance therapy was 13 months(interquartile range,7 to 16 months).The PFS rates at 6 and 12 months were 85.6％and 66.7％,respectively,with a median PFS of 13 months.We failed to reach the median OS within the follow-up period.Among the cohort,five patients received combination therapy with BTK inhibitors,and the other ten patients received therapy with single BTK inhibitor,without obvious difference in the PFS and OS between the two groups.The observed adverse events included leukopenia,anemia,pulmonary infections,and complex urinary tract infections.Conclusion BTK inhibitor monotherapy and combination therapy demonstrate good clinical efficacy and manageable safety profiles in the elderly and infirm patients with PCNSL,which facilitates further clinical application of BTK inhibitors in the elderly.
Bruton's tyrosine kinase inhibitorprimary central nervous system lymphomaclinical efficacysafety
NETL
NSTL
万方数据
